Novo Nordisk

Novo Nordisk Statistics and Facts

Novo Nordisk

Pharmaceutical Industry Statistics and Facts

  • Company Type


  • Establishment Year


  • Headquarters

    Bagsværd, Denmark


    ~48,478 (2022)

  • Industry


  • Revenue

    US$ 20,217.5 Mn (2021)

  • Products

    Diabetes medications, Obesity medication, Insulin pens, Injection needles, Haemophilia medications, Growth disorder medications, Hormone replacement therapy.

  • Subsidiaries

    Dicerna Pharmaceuticals, Novo Nordisk Inc., Emisphere Technologies, Inc., Aldaph SpA, Ziylo Ltd, NNE A/S, Corvidia Therapeutics, Inc., Novo Nordisk Pharmatech A/S, Novo Nordisk Pharma GmbH, Calibrium, LLC, Novo Nordisk Production Sas, Novozymes Biotech, Inc., Novo Nordisk FemCare AG, Steno Diabetes Center A/S, Others.

  • Competitors

    MannKind Corporation, Abbott, Aimmune Therapeutics, Amgen, Gilead Sciences, Sanofi, Biocon, Eli Lilly, Bristol-Myers Squibb, Emcure, Opko Health and Others.

  • Website

Novo Nordisk Statistics: Novo Nordisk A/S is a pharmaceutical company and healthcare provider that produces and markets biomedical medicines for different therapeutic areas. It also sells products in the therapeutic areas for hemophilia and growth hormone therapy. The company is represented in more than 80 countries, including the Americas. Europe, Asia, Middle East, Africa, and Asia. The company markets its products to more than 169 countries. It operates in two business segments: Diabetes and Obesity Care and Biopharmaceuticals. The Diabetes and Obesity Care business segment develops and manufactures insulin, GLP-1 and related delivery methods, oral antidiabetic medicines (OAD), and other drugs. It provides new-generation insulins. FlexTouch (prefilled diabetes delivery system), FlexPen (7-day insulin delivery system), NovoPen 5 (5-day insulin delivery system), NovoPen4 (4-day insulin delivery platform), NovoPen Echo, NovoFine(needle), NovoTwist (needle), and GlucaGen (insulin delivery system); obesity products, like Saxenda; as well oral antidiabetic medications, including NovoNorm (9-day insulin treatment). The Diabetes and Obesity Care section accounted for 85.1% of the company’s FY2020 revenue.

The Biopharmaceuticals division focuses its efforts on the research, development, and manufacturing of products that treat hemophilia. It also offers growth hormone therapy and hormone replacement therapy. It offers hemostasis products such as NovoSeven (recombinant factor VIIa), NovoEight (recombinant factor VIII), and NovoThirteen (recombinant FXIII); human growth hormone products, including Norditropin (somatropin), NordiPen (prefilled multi-dose delivery system), NordiLet (prefilled multi-dose delivery system), and PenMate (prefilled multi-dose delivery system); and hormone replacement therapy products, including Activelle (estradiol/norethisterone acetate), Estrofem (estradiol), Novofem (estradiol/norethisterone acetate), and Vagifem (estradiol hemihydrate). The Biopharmaceuticals section accounted for 14.9% of the company’s FY2020 revenue. The company categorizes its business in two regions. In FY2020 North America accounted for 48.1%, followed by International (51.9%).

Novo Nordisk at a Glance:

  • Novo Nordisk is a global health company with its headquarters in Denmark. The company’s major business is to develop biological medicines.
  • The company was founded on 21 December 1923, a company with a rich heritage of 145 years, headquartered in Denmark.
  • Marketed products are available in 168 countries.
  • The number of employees worldwide is 48,478
  • R&D Facilities are in 5 countries.


Operating profit of Novo Nordisk 2009-2021

Novo Nordisk’s, a Danish pharmaceutical firm that specializes in diabetes medication, reached its peak operating profit in 2021 at 8.43 billion USD. The operating profit fluctuated between 6.79 and 7.11 billion USD through 2018 but increased substantially until 2021.

Net Profit of Novo Nordisk 2012-2021

Novo Nordisk, a Danish pharmaceutical company, saw its net profit increase annually from 2009 to 2021. However, there was a decline from 2016 to 2019. The 2009 net profit was 1.38 billion USD. By 2021, it had risen to 6.76 billion USD.

R&D Costs of Novo Nordisk as Share of Sales 2009-2021

Novo Nordisk, a Danish pharmaceutical firm, spent close to 13% of its total sales in 2021 on research and development costs. This was one of the lowest percentages of sales during the time period. In 2010, 15.8% of all sales were spent on research and development.

Total Assets of Novo Nordisk 2016-2021

The total assets of Novo Nordisk’s Denmark, a Danish biopharmaceutical company, have increased every year between 2016 and 2021. In 2021, total assets reached some 28.01 billion USD.

Novo Nordisk Sales Share by Region 2021

Novo Nordisk, a Danish pharmaceutical company, generated nearly half its North American sales in 2021. China also represents a major single market and accounts for around 11 % of total sales.

Novo Nordisk’s Best-selling Products in 2021

Novo Nordisk, a Danish drug manufacturer, is selling the top product Ozempic. It’s a glucagon-like peptide 1. In 2021, it generated more than 33 billion. Victoza, another GLP-1-related product, was the company’s second-best-selling product.

Geographical Split of Shareholders

Sales by Therapeutic Area

Novo Nordisk’s Diabetes Care Therapeutic Area accounts for 80% of the market share in sales.

Recent Developments:

The year 2021

  • In February, Novo Nordisk and the University of Toronto announced a combined CAD40 million investment to address diabetes and chronic disease prevention.
  • Novo Nordisk, a Danish producer, announced plans to invest DKK 500million to improve facilities at Malov in Denmark.
  • Novo Nordisk & the University of Toronto have announced, in February, a new research hub on U of T’s Mississauga campus.
  • In March, the company and Gilead Sciences announced to expand their collaboration for non-alcoholic steatohepatitis (NASH) to conduct a larger trial.
  • In March, the company entered into a partnership with Tetra Science to design a cloud-based instrument data platform for drug R&D, built natively on Amazon Web Services.
  • Novo Nordisk partnered with Lumen Bioscience to conduct research in June. The purpose of the collaboration was to assess how Lumen’s Spirulina-based drug manufacturing platform can be used in Novo Nordisk’s research on obesity and other metabolic conditions.
  • In July, Novo Nordisk entered into an agreement to acquire Prothena’s investigational drug, PRX004, as well as a wider ATTR amyloidosis Programme for US$1.2 billion.
  • In July, Novo Nordisk entered into an agreement to acquire Neotope Neuroscience Limited from Prothena Biosciences Limited for US$1.23 billion.
  • In September, Novo Nordisk and Biocorp entered into a partnership to develop the Mallya smart add-on device for Novo Nordisk’s FlexTouch pens used by people with diabetes.
  • In December, Novo Nordisk acquired Dicerna Pharmaceuticals.

The year 2020

  • In January, Novo Nordisk entered into a research collaboration with Fauna Bio to discover novel therapeutics for Obesity.
  • In January, Novo Nordisk collaborated with HighRes Bio solutions to design a robotic platform for high-throughput biologics engineering and characterization.
  • In June, Novo Nordisk’s entered into an agreement to acquire Corvidia Therapeutics Inc. from Sofinnova Partners for up to US$2.1 billion.
  • Novo Nordisk revealed in August its plans to invest DKK850million to expand Denmark’s production facilities.
  • In August, Novo Nordisk’s entered into an agreement with SAS Cargo to secure SAS Cargo’s transport of medicines.
  • In September, Novo Nordisk and The American College of Cardiology announced a partnership to improve cardiovascular disease management in patients with type 2 diabetes.
  • In December, Novo Nordisk acquired Emisphere Technologies Inc., a drug delivery company.
  • Novo Nordisk, in December, announced that it had filed a drug application for semaglutide-2.4 mg to the US FDA. It is a glucagon-like peptide-1 analog for chronic weight management.
  • In December, Novo Nordisk and Procyon Technologies entered into a collaboration to develop a stem-cell-based therapy for Type 1 diabetes.
  • Novo Nordisk submitted in December to the European Medicines Agency to approve its semaglutide 2,4 mg for use in weight control.

Share This Statistics


Medical Device Industry/Brands Statistics and Facts


Eli Lilly and Company Statistics and Facts